GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Medite Cancer Diagnostics Inc (OTCPK:MDIT) » Definitions » PS Ratio

Medite Cancer Diagnostics (Medite Cancer Diagnostics) PS Ratio : 0.00 (As of May. 19, 2024)


View and export this data going back to . Start your Free Trial

What is Medite Cancer Diagnostics PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Medite Cancer Diagnostics's share price is $0.0001. Medite Cancer Diagnostics's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2018 was $0.18. Hence, Medite Cancer Diagnostics's PS Ratio for today is 0.00.

The historical rank and industry rank for Medite Cancer Diagnostics's PS Ratio or its related term are showing as below:

MDIT's PS Ratio is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 3.3
* Ranked among companies with meaningful PS Ratio only.

Medite Cancer Diagnostics's Revenue per Sharefor the three months ended in Sep. 2018 was $0.03. Its Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2018 was $0.18.

Back to Basics: PS Ratio


Medite Cancer Diagnostics PS Ratio Historical Data

The historical data trend for Medite Cancer Diagnostics's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medite Cancer Diagnostics PS Ratio Chart

Medite Cancer Diagnostics Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17
PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.33 4.69 2.36 1.18 1.16

Medite Cancer Diagnostics Quarterly Data
Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.54 1.16 0.70 0.97 1.12

Competitive Comparison of Medite Cancer Diagnostics's PS Ratio

For the Medical Instruments & Supplies subindustry, Medite Cancer Diagnostics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medite Cancer Diagnostics's PS Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Medite Cancer Diagnostics's PS Ratio distribution charts can be found below:

* The bar in red indicates where Medite Cancer Diagnostics's PS Ratio falls into.



Medite Cancer Diagnostics PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Medite Cancer Diagnostics's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=0.0001/0.178
=0.00

Medite Cancer Diagnostics's Share Price of today is $0.0001.
Medite Cancer Diagnostics's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.18.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Medite Cancer Diagnostics  (OTCPK:MDIT) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Medite Cancer Diagnostics PS Ratio Related Terms

Thank you for viewing the detailed overview of Medite Cancer Diagnostics's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Medite Cancer Diagnostics (Medite Cancer Diagnostics) Business Description

Traded in Other Exchanges
N/A
Address
4203 SouthWest 34th Street, Orlando, FL, USA, 32811
Medite Cancer Diagnostics Inc is a US-based company which specializes in the marketing and selling of MEDITE core products (instruments and consumables), manufacturing, development of new solutions in histology and cytology and marketing of molecular biomarkers. The company manufactures medical devices and consumables are for detection, risk assessment and diagnosis of cancerous and precancerous conditions and related diseases. Medite operates through the single segment for cancer diagnostics instruments and consumables for histology and cytology laboratories. It offers a range of histology laboratory devices for processing tissue, from receiving the tissue in the laboratory to the final diagnosis.
Executives
Lewis William Austin Iv director, 10 percent owner 201 E 87TH STREET, APT 5H, NEW YORK NY 10128
John H Abeles director 2365 NW 41ST STREET BOCA RATON FL 33431
Joel S Kanter director C/O APPLIED UV, INC., 150 N. MACQUESTEN PKWY, MOUNT VERNON NY 10550
Clinton Severson director C/O ABAXIS INC, 3240 WHIPPLE ROAD, UNION CITY CA 94587

Medite Cancer Diagnostics (Medite Cancer Diagnostics) Headlines

No Headlines